TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Sab Biotherapeutics, Inc.
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

SAB Biotherapeutics reported positive Phase 1 trial results for SAB-142, a potential treatment for type 1 diabetes, demonstrating safety, low immunogenicity, and no serum sickness across healthy volunteers and patients.

Insights
QBTS.WS   neutral

Mentioned in related articles, but no specific details about performance were provided in the main article


SABS   positive

Successful Phase 1 trial results, no serious adverse events, advancing to Phase 2b SAFEGUARD trial, positive commentary from leadership indicating promising therapeutic potential